The Life Sciences team advised Intellia Therapeutics, Inc.(Nasdaq:NTLA), on the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a public offering price of $24.00 per share, before underwriting discounts. Intellia also granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stock. The gross proceeds from the offering, before deducting underwriting discounts and estimated offering expenses, are expected to be $150 million, excluding any exercise of the underwriters’ option to purchase additional shares.
Goodwin has a long-standing relationship with Intellia Therapeutics since its formation in 2014, through major collaborations with Novartis and Regeneron and last year’s $108 million IPO and $55 million simultaneous private placement, which is considered among the most successful biotech IPOs of 2016.
Intellia Therapeutics is a leading genome editing company focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system.
The Goodwin cross disciplinary team was led by partner William Collins, Janet Andolina and Martin Carmichael; and associates Gabriela Morales-Rivera and Riley Lovendale.
For more information on the offering, please read the press release.